FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1458-1459 November 24, 1994 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Guerina, N. G. PubMed Citation

To the Editor: Guerina et al. (June 30 issue)¹ claim a "favorable" cost-benefit ratio for neonatal screening for congenital toxoplasmosis, but their data are inadequate. Although they mention laboratory and personnel costs, they do not include the added costs of confirming the diagnosis, reporting and treating the disease, counseling families, training clinical personnel, and tracking cases. Moreover, the data presented are not sufficient to determine whether there are any savings in either medical costs or lifetime social costs.

In the study by Guerina et al., the incidence of congenital toxoplasmosis in Massachusetts and New Hampshire was 10 times lower than . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.